You just read:

Boston Biomedical Initiates CanStem111P: A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer

News provided by

Boston Biomedical, Inc.

Feb 21, 2017, 08:00 ET